logo

Theravance Biopharma Inc. (TBPH)



Trade TBPH now with
  Date
  Headline
1/28/2019 8:35:51 AM Theravance : First Patient Dosed In Registrational Phase 3 Study Of Ampreloxetine For The Treatment Of Symptomatic NOH
12/13/2018 7:30:47 AM Jeff Jonker Joins Ambys Medicines As President And CEO
11/27/2018 7:56:08 AM Theravance Announces First Subject Dosed In Phase 1 Trial Of TD-8236, A Novel Inhaled Pan-JAK Inhibitor
11/20/2018 8:35:27 AM Theravance Announces First Patient Dosed In Phase 2 Study Of TD-1473 In Patients With Crohn's Disease
11/9/2018 3:36:00 PM Theravance, Mylan Get FDA Approval For YUPELRI In Adults With Chronic Obstructive Pulmonary Disease
10/11/2018 8:32:20 AM Theravance Biopharma, Mylan Report Positive New Data From Multiple Studies Of YUPELRI At 2018 CHEST Annual Meeting
10/10/2018 8:35:41 AM Theravance Biopharma Announces Data From Phase 1b Study Of TD-1473 Selected For Oral Late-Breaker Presentation At UEG
10/8/2018 8:33:51 AM Theravance Biopharma And Mylan To Present New Data From Studies Of YUPELRI
10/8/2018 7:31:50 AM Theravance Biopharma Reports Positive New Data From Multiple Studies Of VIBATIV At IDWeek 2018
9/17/2018 8:33:09 AM Theravance Biopharma And Mylan Report New Data From Phase 3 Studies Of YUPELRI
4/25/2018 8:38:53 AM Theravance Biopharma Highlight That FDA Approved Expanded Indication For Trelegy Ellipta
4/17/2018 8:32:54 AM Theravance Biopharma To Present New Data From Multiple Studies Of VIBATIV At 2018 ECCMID™ Conference